Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance (PERSEUS)
The PERSEUS Registry - Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy). It collects data generated during routine care across the whole course of the disease: pre-hospital care when available, emergency department presentation, the hospital stay (including bedside reassessments in the first 48 hours when performed as part of care) and follow-up up to 5 years. The registry has a retrospective cohort (patients diagnosed from 1 January 2023 until local ethics committee approval, with data taken from medical records) and a prospective cohort (consecutive patients enrolled after approval). Taking part in the registry does not change patient care: all tests and treatments are decided by the treating physicians. The registry aims to describe how acute PE is managed in everyday practice and how often patients die (from any cause and from PE), deteriorate hemodynamically, have recurrent venous thromboembolism or bleeding, and develop long-term complications such as chronic thromboembolic pulmonary hypertension. The database also supports ancillary analyses with separate pre-specified analysis plans, such as the evaluation of existing risk-stratification tools.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
BACKGROUND AND SCIENTIFIC RATIONALE
Pulmonary embolism (PE) represents a major cause of emergency department (ED) presentation, critical care admission, and early mortality. Despite advances in diagnostic algorithms and therapeutic strategies, intermediate- and high-risk PE patients remain challenging to risk-stratify dynamically during the acute phase. Current prognostic tools often rely solely on baseline single-point parameters, neglecting acute pathophysiological changes during the initial 48 hours of treatment. The PERSEUS Registry is designed to bridge this gap by capturing comprehensive, granular real-world data spanning the acute presentation, dynamic in-hospital course, and long-term surveillance.
STUDY DESIGN AND COHORTS
Time perspective: ambispective (retrospective and prospective cohorts, described below).
PERSEUS is an observational, ambispective, multicenter registry comprising two distinct phases:
- Retrospective Phase (Historical Cohort): Includes consecutive adult patients diagnosed with acute PE from January 1, 2023, up to the date of local Ethics Committee approval at each participating site. Data are abstracted from medical records.
- Prospective Phase (Contemporary Cohort): Enrolls consecutive adult patients presenting with acute PE after local Ethics Committee approval, extending for a continuous enrollment period of 5 years. Data are collected during routine care.
STUDY SETTING AND CLINICAL CONTINUUM OF CARE
Data collection spans the entire continuum of clinical care across participating academic, tertiary, and regional hospitals:
- Baseline Presentation (T0): Captures pre-hospital emergency medical service (EMS) data (initial vital signs, cardiac arrest, point-of-care ultrasound [POCUS], pre-hospital anticoagulation or thrombolysis), ED arrival parameters, clinical symptoms, arterial blood gas analysis, admission laboratory biomarkers (high-sensitivity troponin, BNP/NT-proBNP, lactate, D-dimer, renal function), electrocardiographic patterns, and multiorgan diagnostic imaging (CT pulmonary angiography [CTPA], complete echocardiography/POCUS, and compression venous ultrasound [CUS]).
- Dynamic In-Hospital Reassessment (T1-T4): To capture real-world hemodynamic and respiratory trajectories, serial parameters documented during standard clinical monitoring are recorded across predefined temporal windows: T1 (3-6 hours), T2 (6-12 hours), T3 (12-24 hours), and T4 (24-48 hours). Parameters include serial vital signs, shock index, respiratory support modalities, serial lactate/troponin kinetics, echocardiographic right ventricular function changes, and need for escalating hemodynamic or respiratory support (vasopressors, inotropes, non-invasive ventilation, mechanical ventilation, or ECMO).
- Hospital Discharge & Complications: Documents in-hospital adverse events, need for rescue reperfusion, procedural complications, bleeding events, length of stay, and vital status at discharge.
- Follow-up Surveillance: Thirty-day status is ascertained from clinical records. Follow-up then reflects routine care at 3 and 12 months and annually thereafter up to 5 years (in-person visit, telemedicine, telephone contact or review of clinical documentation), with regional mortality registries used to ascertain vital status when needed. Follow-up collects all-cause survival, cause of death, VTE recurrence, major and clinically relevant non-major bleeding, persistent functional limitation (modified Rankin Scale, exertional dyspnea, six-minute walk test when performed) and the development of chronic thromboembolic pulmonary hypertension (CTEPH).
OUTCOMES
Outcome definitions and time frames are reported in the Outcome Measures section.
DATA MANAGEMENT, QUALITY ASSURANCE, AND ETHICAL GOVERNANCE
Data collection is centralized using an electronic Case Report Form (eCRF) deployed on the REDCap (Research Electronic Data Capture) platform hosted on secure institutional servers at Azienda Ospedaliero-Universitaria Careggi (Florence, Italy).
- Privacy and Data Segregation: Strict GDPR compliance is maintained. Patient data are pseudonymized at source by the local site investigator using site-specific Subject IDs. The decoding key linking the alphanumeric ID to personal identifiers is maintained exclusively at the local participating hospital under the responsibility of the local Principal Investigator.
- Data Access Groups (DAGs): REDCap DAGs are enforced to compartmentalize site-level access, ensuring participating centers can exclusively view, enter, and edit their own center's records, with no unauthorized cross-center data visibility.
- Quality Assurance: The eCRF includes built-in validation rules (range and logic checks). The coordinating center performs regular central monitoring for inconsistencies, outliers and missing data, and discrepancies are resolved with each center through a formal query process. The Steering Committee reviews enrollment, data quality and protocol adherence every 6 months.
- Regulatory Framework: Protocol version 2.0 (7 May 2026) received a favourable opinion from the Comitato Etico Regione Toscana - Area Vasta Centro (CEAVC, register no. 30742_oss, meeting of 9 June 2026) for the sites of Azienda Ospedaliero-Universitaria Careggi and Azienda USL Toscana Centro. Participation of other national and international centers is subject to approval of a protocol amendment and of the competent local ethics committees. The study is conducted in accordance with the Declaration of Helsinki, Good Clinical Practice principles and applicable privacy regulations (including Article 110-bis of the Italian Privacy Code).
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Simone Vanni, MD, PhD
- Numéro de téléphone: +393666904459
- E-mail: simone.vanni@unifi.it
Sauvegarde des contacts de l'étude
- Nom: Matteo Gabriele Monda, MD
- Numéro de téléphone: +393209433394
- E-mail: matteogabriele.monda@gmail.com
Lieux d'étude
-
-
-
Madrid, Espagne
- Recrutement
- Hospital Universitario Ramón y Cajal
-
Contact:
- David Jiménez, MD, PhD
- Numéro de téléphone: +34913368000
- E-mail: djimenez.hrc@gmail.com
-
Chercheur principal:
- David Jiménez, MD, PhD
-
-
-
-
-
Lido di Camaiore, Italie
- Recrutement
- Ospedale Versilia - Azienda USL Toscana Nord Ovest
-
Contact:
- Gisueppe Pepe, MD
- Numéro de téléphone: +3905846051
- E-mail: giuseppe.pepe@uslnordovest.toscana.it
-
Chercheur principal:
- Giuseppe Pepe, MD
-
Naples, Italie, 80131
- Recrutement
- AORN Antonio Cardarelli
-
Contact:
- Angela Iannuzzi, MD
- Numéro de téléphone: +390817471111
- E-mail: angela.iannuzzi@aocardarelli.it
-
Chercheur principal:
- Angela Iannuzzi, MD
-
Perugia, Italie, 06129
- Recrutement
- Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia
-
Contact:
- Cecilia Becattini, MD, PhD
- Numéro de téléphone: +390755781
- E-mail: cecilia.becattini@unipg.it
-
Chercheur principal:
- Cecilia Becattini, MD, PhD
-
Pisa, Italie
- Recrutement
- Azienda Ospedaliero-Universitaria Pisana - Ospedale Cisanello
-
Contact:
- Lorenzo Ghiadoni, MD, PhD
- Numéro de téléphone: +39050992111
- E-mail: lorenzo.ghiadoni@unipi.it
-
Chercheur principal:
- Lorenzo Ghiadoni, MD, PhD
-
Torino, Italie, 10126
- Recrutement
- AOU Città della Salute e della Scienza di Torino - Presidio Molinette
-
Contact:
- Fulvio Morello, MD
- Numéro de téléphone: +390116335555
- E-mail: fulvio.morello@unito.it
-
Chercheur principal:
- Fulvio Morello, MD
-
-
Tuscany
-
Bagno a Ripoli, Tuscany, Italie, 50012
- Recrutement
- Ospedale Santa Maria Annunziata - Azienda USL Toscana Centro
-
Contact:
- Germana Ruggiano, MD
- Numéro de téléphone: +39 055 69361
- E-mail: germana.ruggiano@uslcentro.toscana.it
-
Borgo San Lorenzo, Tuscany, Italie, 50032
- Recrutement
- Nuovo Ospedale del Mugello - Azienda USL Toscana Centro
-
Contact:
- Leonardo Delli, MD
- Numéro de téléphone: +39 055 84511
- E-mail: leonardo.delli@uslcentro.toscana.it
-
Empoli, Tuscany, Italie, 50053
- Recrutement
- Ospedale San Giuseppe - Azienda USL Toscana Centro
-
Contact:
- Paola Bartalucci, MD
- Numéro de téléphone: +39 0571 7051
- E-mail: paola.bartalucci@uslcentro.toscana.it
-
Florence, Tuscany, Italie, 50134
- Recrutement
- Azienda Ospedaliero-Universitaria Careggi
-
Contact:
- Simone Vanni, MD, PhD
- Numéro de téléphone: +393666904459
- E-mail: simone.vanni@unifi.it
-
Contact:
- Matteo Gabriele Monda, MD
- Numéro de téléphone: +393209433394
- E-mail: matteogabriele.monda@gmail.com
-
Chercheur principal:
- Simone Vanni, MD, PhD
-
Sous-enquêteur:
- Matteo Gabriele Monda, MD
-
Florence, Tuscany, Italie, 50122
- Recrutement
- Ospedale Santa Maria Nuova - Azienda USL Toscana Centro
-
Contact:
- Michele Lanigra, MD
- Numéro de téléphone: +39 055 69381
- E-mail: michele.lanigra@uslcentro.toscana.it
-
Florence, Tuscany, Italie, 50143
- Recrutement
- Ospedale San Giovanni di Dio (Torregalli) - Azienda USL Toscana Centro
-
Contact:
- Gianfranco Giannasi, MD
- Numéro de téléphone: +39 055 69321
- E-mail: gianfranco.giannasi@uslcentro.toscana.it
-
Pescia, Tuscany, Italie, 51017
- Recrutement
- Ospedale Santi Cosma e Damiano - Azienda USL Toscana Centro
-
Contact:
- Gianluca Buffini, MD
- Numéro de téléphone: +39 0572 4601
- E-mail: gianluca.buffini@uslcentro.toscana.it
-
Pistoia, Tuscany, Italie, 51100
- Recrutement
- Ospedale San Jacopo - Azienda USL Toscana Centro
-
Contact:
- Mirco Donati, MD
- Numéro de téléphone: +39 0573 3521
- E-mail: mirco.donati@uslcentro.toscana.it
-
Prato, Tuscany, Italie, 59100
- Recrutement
- Ospedale Santo Stefano - Azienda USL Toscana Centro
-
Contact:
- Matteo Gabriele Monda, MD
- Numéro de téléphone: +393209433394
- E-mail: matteogabriele.monda@gmail.com
-
Contact:
- E-mail: matteogabriele.monda@gmail.com
-
Chercheur principal:
- Simone Magazzini, MD
-
-
-
-
-
Warsaw, Pologne
- Recrutement
- Medical University of Warsaw - Infant Jesus Teaching Hospital
-
Contact:
- Piotr Pruszczyk, MD, PhD
- Numéro de téléphone: +48225021000
- E-mail: piotr.pruszczyk@wum.edu.pl
-
Chercheur principal:
- Piotr Pruszczyk, MD, PhD
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Consecutive adults with objectively confirmed acute pulmonary embolism diagnosed at participating hospitals, from emergency department presentation through hospitalization, including patients presenting with obstructive shock or cardiac arrest.
La description
Inclusion Criteria:
- Age 18 years or older at the time of presentation.
- Objectively confirmed diagnosis of acute pulmonary embolism (PE), with or without concomitant deep vein thrombosis (DVT) of the lower or upper extremities, confirmed by at least one of the following methods:
- Computed tomography pulmonary angiography (CTPA) demonstrating intraluminal filling defects in the pulmonary arterial tree;
- Ventilation/perfusion (V/Q) lung scintigraphy demonstrating high-probability mismatch;
- Conventional catheter-directed pulmonary angiography;
- In hemodynamically unstable patients (obstructive shock or cardiac arrest) in whom definitive imaging is not feasible: bedside point-of-care ultrasound showing clear signs of right ventricular overload together with proximal deep vein thrombosis, or mobile right heart thrombi.
- For the retrospective cohort: availability of medical records documenting clinical presentation and index diagnostic work-up at baseline (T0). The absence of serial reassessment timepoints (T1-T4) does not constitute an exclusion criterion.
- Written informed consent obtained from the patient or legal surrogate, or waiver/exception under Article 110-bis of the Italian Privacy Code (and applicable institutional ethical clearance) for deceased or untraceable patients.
Exclusion Criteria:
- Current active enrollment in an interventional experimental drug trial (blinded randomized clinical trial) where active drug allocation or protocol-mandated therapeutic regimen is unknown.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: OTHER
Nombre de groupes / cohortes
Cohortes et interventions
Groupe / CohorteGroupe / Cohorte |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Adults with acute pulmonary embolism
Consecutive adults with objectively confirmed acute pulmonary embolism, in two cohorts: a retrospective cohort (diagnoses from 1 January 2023 until local ethics committee approval; data abstracted from medical records) and a prospective cohort (consecutive enrollment after approval, for 5 years; data collected during routine care). |
Observational registry. Diagnostic and therapeutic management (laboratory tests, imaging, bedside ultrasound, anticoagulation, reperfusion and hemodynamic support) is entirely at the discretion of the treating physicians, according to routine institutional pathways and international guidelines. The registry only collects data generated in routine care.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
All-cause mortality at 30 days
Délai: 30 days after diagnosis
|
Proportion of patients who die from any cause within 30 days of the objectively confirmed diagnosis of acute pulmonary embolism. Vital status is ascertained from hospital records, review of clinical documentation and, when needed, regional mortality registries. |
30 days after diagnosis
|
|
PE-related mortality at 30 days
Délai: 30 days after diagnosis
|
Proportion of patients whose death within 30 days is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism (PE). Fatal PE is defined as death occurring after objectively confirmed PE (index or recurrent event) in the absence of other identifiable causes, or confirmed at autopsy. For deaths occurring at home, information on the cause of death is actively sought. |
30 days after diagnosis
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Hemodynamic decompensation
Délai: From diagnosis to hospital discharge or day 30, whichever comes first
|
Proportion of patients with new occurrence, after the initial assessment, of at least one of: persistent hypotension (systolic blood pressure <90 mmHg for 15 minutes or longer) or shock; need for continuous vasopressor or inotrope infusion; invasive mechanical ventilation; cardiac arrest; rescue reperfusion therapy (systemic, catheter-directed or surgical) for clinical deterioration. Reperfusion given as the initial treatment strategy is not counted as an event. |
From diagnosis to hospital discharge or day 30, whichever comes first
|
|
All-cause mortality during follow-up
Délai: 3 months, 12 months, and annually up to 5 years after diagnosis
|
Proportion of patients who die from any cause during follow-up. |
3 months, 12 months, and annually up to 5 years after diagnosis
|
|
PE-related mortality during follow-up
Délai: 3 months, 12 months, and annually up to 5 years after diagnosis
|
Proportion of patients whose death during follow-up is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism, as defined for the 30-day PE-related mortality outcome. |
3 months, 12 months, and annually up to 5 years after diagnosis
|
|
Recurrent venous thromboembolism
Délai: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
Proportion of patients with any new episode of pulmonary embolism or deep vein thrombosis (lower or upper limb, proximal or distal) confirmed by objective testing. Superficial vein thrombosis is not counted. |
30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
|
Major bleeding (ISTH criteria)
Délai: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
Proportion of patients with major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH): overt bleeding that is fatal; or occurs in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome); or causes a fall in hemoglobin of 2 g/dL (1.24 mmol/L) or more, or leads to transfusion of two or more units of whole blood or red cells. Major bleeding is additionally classified as life-threatening if it is extracranial bleeding causing shock or intracranial hemorrhage with a Glasgow Coma Scale score below 14. |
30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
|
Clinically relevant non-major bleeding
Délai: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
Proportion of patients with bleeding not meeting the criteria for major bleeding but requiring medical intervention, unscheduled contact with a physician, or temporary cessation of antithrombotic therapy. |
30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
|
Chronic thromboembolic pulmonary hypertension (CTEPH)
Délai: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
Proportion of patients with CTEPH diagnosed during routine follow-up: mean pulmonary arterial pressure >20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg and pulmonary vascular resistance >2 Wood units at right heart catheterization, with mismatched perfusion defects after at least 3 months of therapeutic anticoagulation (2022 ESC/ERS criteria). Diagnostic tests are performed only when clinically indicated. |
30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
|
Persistent functional limitation after pulmonary embolism (post-PE syndrome)
Délai: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
Persistent or worsened exertional dyspnea compared with pre-event status, modified Rankin Scale score, and six-minute walk distance when performed in routine care. |
30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Simone Vanni, MD, PhD, Azienda Ospedaliero-Universitaria Careggi / University of Florence
- Directeur d'études: Matteo Gabriele Monda, MD, Azienda Ospedaliero-Universitaria Careggi / University of Florence
Publications et liens utiles
Publications générales
- Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):370-2. doi: 10.1161/ATVBAHA.108.162545. No abstract available.
- Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999 Apr 24;353(9162):1386-9. doi: 10.1016/s0140-6736(98)07534-5.
- Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jimenez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ni Ainle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. doi: 10.1093/eurheartj/ehz405. No abstract available.
- Jimenez D, de Miguel-Diez J, Guijarro R, Trujillo-Santos J, Otero R, Barba R, Muriel A, Meyer G, Yusen RD, Monreal M; RIETE Investigators. Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry. J Am Coll Cardiol. 2016 Jan 19;67(2):162-170. doi: 10.1016/j.jacc.2015.10.060.
- Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Radegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237. No abstract available.
- Barco S, Mahmoudpour SH, Valerio L, Klok FA, Munzel T, Middeldorp S, Ageno W, Cohen AT, Hunt BJ, Konstantinides SV. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med. 2020 Mar;8(3):277-287. doi: 10.1016/S2213-2600(19)30354-6. Epub 2019 Oct 12.
- Franco L, Becattini C, Beyer-Westendorf J, Vanni S, Nitti C, Re R, Manina G, Pomero F, Cappelli R, Conti A, Agnelli G. Definition of major bleeding: Prognostic classification. J Thromb Haemost. 2020 Nov;18(11):2852-2860. doi: 10.1111/jth.15048. Epub 2020 Sep 11.
- Vanni S, Pelagatti L, Caviglioli C, Fabiani G, Caldi F, Pellegrino A, Ottaviani M, Innocenti F, Nazerian P. TELOS-plus identifies normotensive patients with pulmonary embolism at high risk of 30-day mortality. Int J Cardiol. 2026 Feb 1;444:133974. doi: 10.1016/j.ijcard.2025.133974. Epub 2025 Oct 22.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- Département d'urgence
- Thromboembolie veineuse
- Échocardiographie
- Stratification des risques
- Arrêt cardiaque
- Registre d'observation
- Embolie pulmonaire aiguë
- Embolie pulmonaire
- Échographie au point de service
- Dysfonctionnement ventriculaire droit
- Preuve du monde réel
- Directives ESC
- Soins préhospitaliers d'urgence
- Cohorte Ambispective
- CT Pulmonary Angiography
- Prognostic Scores
- TELOS-plus
- sPESI
- Bova Score
- AHA/ACC Guidelines
- High-Sensitivity Troponin
- Plasma Lactate
- Hemodynamic Decompensation
- Systemic Thrombolysis
- Catheter-Directed Therapy
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Maladies cardiaques
- Attributs de la maladie
- Maladies des voies respiratoires
- Maladies pulmonaires
- Embolie et thrombose
- Embolie
- Dysfonctionnement ventriculaire
- Thromboembolie
- Conditions pathologiques, signes et symptômes
- Urgences
- Embolie pulmonaire
- Arrêt cardiaque
- Thromboembolie veineuse
- Dysfonction ventriculaire droite
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- PERSEUS
- 30742_oss (Autre identifiant: Ethics Committee Approval ID (Comitato Etico Regione Toscana - Area Vasta Centro, CEAVC))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Pseudonymized individual participant data underlying published results may be shared with qualified researchers for methodologically sound proposals that fall within the scientific scope of the registry and do not overlap with analyses planned by the PERSEUS investigators. Sharing requires approval by the PERSEUS Steering Committee, approval by the competent ethics committee and a data transfer agreement with Azienda Ospedaliero-Universitaria Careggi, in compliance with the GDPR and the Italian Privacy Code.
Délai de partage IPD
Data will become available beginning 12 months after formal publication of the primary registry outcomes manuscript and will remain accessible for a period of 5 years.
Critères d'accès au partage IPD
Access requests must be submitted in writing to the Principal Investigator (simone.vanni@unifi.it) and the PERSEUS Steering Committee, including a detailed scientific protocol and statistical analysis plan. Proposals will be evaluated for scientific merit, feasibility, ethical compliance, and non-redundancy by the Steering Committee. Prior to data release, requestors and their home institutions must sign a formal Data Transfer Agreement (DTA) with Azienda Ospedaliero-Universitaria Careggi and obtain appropriate local ethical approval.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .